U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer

Largest Kidney Patient Group Applauds HHS Secretary Robert F. Kennedy Jr.'s Appointments to the U.S. Preventive Services Task Force

BIOCYTICS AND EREMID GENOMIC SERVICES COLLABORATE ON RESEARCH STUDY FOR NOVEL SINGLE-CELL TRANSCRIPTOMICS IMMUNE-BASED CANCER CELL THERAPY

NAVER D2SF Invests in AI-Driven Precision Medicine Company ImpriMed

Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)